Cardiovascular risk factors: Hemorheologic and hemostatic components;Factores de risco cardiovascular: Componentes hemorreológicos e hemostasiológicos

Revista Portuguesa de Cardiologia

Volumn 26, Issue 2, 2007, Pages 161-182

  Martins E Silva, J ^a   Saldanha, Carlota ^b  

^a INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^b NONE

Author keywords

Biomarkers; Cardiovascular disease; Hemorheology; Risk factors

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN;

BLOOD RHEOLOGY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE PREDISPOSITION; HEMOSTASIS; REVIEW; RISK FACTOR;

EID: 34247248899     PISSN: 08702551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (168)

1. Kannel W.B. - Clinical misconceptions dispelled by epidemiological research. Circulation. 1995; 92:3350-3360.
2. Keys S.A. - "Seven Countries: a Multivariate Analysis of Death and Coronary Heart Disease", Cambridge, MA: Harvard University Press 1980.
3. Dawber T.R., Meadors G.F., Moore F.E. Jr. - Epidemiological approaches to heart disease: the Framingham Study - Am. J. Public. Health 1951; 41:279-281.
4. The Pooling Project Research Group. - Relationship of blood pressure, serum cholesterol, smoking habit, relative weight and ECG abnormalities to the incidence of major coronary events: final report of the pooling project. J Chronic Dis. 1978; 31:201-306.
5. Werko L. - Risk factors and coronary heart disease: facts or fancy? Am. Heart J. 1976; 91:87-91.
6. Kannel W.B. - Some lessons in cardiovascular epidemiology from Framingham. Am. J. Cardiol. 1976; 37:269-282.
7. Kannel W.B., Dawber T.R., Kagan A., Revotskie N., Stokes J. 3rd - Factors of risk in the development of coronary heart disease-six year follow-up experience. The Framingham Study. Ann. Intern. Med. 1961; 55:33-50.
8. Stampfer M.J., Ridker P.M., Dzau V.J. - Risk factor criteria. Circulation. 2004; 109 (Suppl 1):IV3-IV5.
9. Grundy S.M. - Age as a risk factor: you are as old as your arteries. Am. J. Cardiol. 1999; 83:1455-1457.
10. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. JAMA. 2001; 285:2486-2497.
11. Wilson P.W., D'Agostino R.B., Levy D., Belanger A.M., Silbershatz H., Kannel W.B. - Prediction of coronary heart disease using risk factor categories. Circulation. 1998; 97:1837-1847.
12. Gordon T, Kannel W.B. - Premature mortality from coronary heart disease: the Framingham study. JAMA. 1971; 215:1617-1625.
13. Oliver M. - Dietary cholesterol, plasma cholesterol and coronary heart disease. Br Heart J. 1976; 38:214-218.
14. Kannel W.B., Dawber T.R., Friedman G.D., Glennon W.E., McNamara P.M. - Risk factors in coronary heart disease. An evaluation of several serum lipids as predictors of coronary heart disease; the Framingham study. Ann. Intern. Med. 1964; 61:888-899.
15. Castelli W.P., Doyle J.T., Gordon T, Hames C.G., Hjortland M.C., Hulley S.B., Kagan A., Zukel W.J. - HDL cholesterol and other lipids in coronary heart disease: the Cooperative Lipoprotein Phenotyping Study. Circulation. 1977; 55:767-772.
16. Kannel W.B., Wilson P.W.F. - Efficacy of lipid profiles in the prediction of coronary disease. Am Heart J. 1992; 124:768-774.
17. Pfeffer M.A., Sacks F.M., Moye L.A., Brown L., Rouleau J.L., Hartley L.H., Rouleau J., Grimm R., Sestier F., Wickemeyer W., et al. Cholesterol and Recurrent Events: a secondary prevention trial for normolipidemic patients. CARE Investigators. Am. J. Cardiol. 1995; 76:98C-106C.
18. Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A., Langendorfer A., Stein E.A., Kruyer W., Gotto A.M. Jr. - Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998; 279:1615-1622.
19. Koch-Weser J. - The therapeutic challenge of systolic hypertension. N Engl J Med. 1973; 289:481-482.
20. Vaisrub S. - Labile and systolic hypertension: a reappraisal. JAMA. 1981; 245:1250. Editorial.
21. Denny-Brown D. - Symposium on specific methods of treatment: treatment of recurrent cerebrovascular symptoms and the questions of "vasospasm". Med. Clin. North. Am. 1951; 35:1457-1474
22. Collins R., Peto R., MacMahon S., Hebert P., Fiebach N.H., Eberlein K.A., Godwin J., Qizilbash N., Taylor J.O., Hennekens C.H. - Blood pressure, stroke and coronary heart disease, 2: short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet. 1990; 335:827-838.
23. Frohlich E.D., Emmott C, Hammarsten J.E., Linehan M, Pollack D, Horsley A.W. - The disregard of abnormal arterial pressure in randomly selected hospitalized patients. Clin. Res. 1970; 18:629.
24. Lew E.A. - High blood pressure, other risk factors and longevity: the insurance viewpoint. Am. J. Med. 1973; 55:281-294.
25. Yano K., McGee D., Reed D.M. - The impact of elevated blood pressure upon 10-year mortality among Japanese men in Hawaii: the Honolulu Heart Program. J. Chronic. Dis. 1983; 36:569-579.
26. Kannel W.B., Vasan R.S., Levy D. - Is the relation of systolic blood pressure to risk of cardiovascular disease continuous and graded, or are there critical values? Hypertension. 2003; 42:453-456.
27. Lawes CM., Bennett D.A., Lewington S., Rodgers A. - Blood pressure and coronary heart disease: a review of the evidence. Semin. Vasc. Med. 2002; 2:355-368.
28. Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo J.L. Jr, Jones D.W., Materson B.J., Oparil S., Wright J.T Jr, Roccella E.J.; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. - Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003; 42:1206-1252.
29. Garcia M.J., McNamara P.M., Gordon T, Kannel W.B. - Cardiovascular complications in diabetics. Adv. Metab. Disorders. 1973; suppl 2:493-499.
30. Wilson P.W.F., Cupples L.A., Kannel W.B. - Is hyperglycemia associated with cardiovascular disease? The Framingham study. Am. Heart. J. 1991; 121:586-590.
31. Meigs J.B., Nathan D.M., D'Agostino R.B. Sr, Wilson P.W.; Framingham Offspring Study - Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study. Diabetes Care. 2002; 25:1845-1850.
32. Blake D.R., Meigs J.B., Muller D.C., Najjar S.S., Andres R., Nathan D.M. - Impaired glucose tolerance, but not impaired fasting glucose, is associated with increased levels of coronary heart disease risk factors: results from the Baltimore Longitudinal Study on Aging. Diabetes. 2004; 53:2095-2100.
33. Dawber T.R., Kannel W.B., Revotskie N., Stokes J. III, Kagan A, Gordon T. - Some factors associated with the development of coronary heart disease. Am J Public. Health. 1959; 49:1349-1356.
34. Doyle J.T., Dawber T.R., Kannel W.B., Heslin A.S., Kahn H.A. - Cigarette smoking and coronary heart disease: combined experience of the Albany and Framingham studies. N. Engl. J. Med. 1962; 266:796-801.
35. Khot U.N., Khot M.B., Bajzer C.T., Sapp S.K., Ohman E.M., Brener S.J., Ellis S.G., Lincoff A.M., Topol E.J. - Prevalence of conventional risk factors in patients with coronary heart disease. JAMA. 2003; 290:898-904.
36. Cole J.H., Miller J.I. III, Sperling L.S., Weintraub W.S. - Long-term follow-up of coronary artery disease presenting in young adults. J. Am. Coll. Cardiol. 2003; 41:521-528.
37. Marks H.H. - Influence of obesity on morbidity and mortality. Bull N Y Acad Med. 1960; 36:296-312
38. Gillum R.F. - The association of body fat distribution with hypertension, hypertension heart disease, coronary heart disease, diabetes and cardiovascular risk factors in men and women aged 18-79 years. J Chron Dis. 1987; 40:421-428.
39. Morris J.N., Raffle P.A.B., Roberts C.G., Parks J.W. - Coronary heart-disease and physical activity of work. Lancet. 1953; 2:1053-1057.
40. Curfman G.D. - Is exercise beneficial - or hazardous - to your heart? N. Engl. J. Med. 1993; 329:1730-1731.
41. Paffenbarger R.S. Jr, Wing A.L., Hyde R.T. - Physical activity as an index of heart attack risk in college alumni. Am. J. Epidemiol. 1978; 108:161-175.
42. Hakim A.A., Petrovitch H., Burchfiel C.M., Ross G.W., Rodriguez B.L., White L.R., Yano K., Curb J.D., Abbott R.D. - Effects of walking on mortality among nonsmoking retired men. N. Engl. J. Med. 1998; 338:94-99
43. Manson J.E., Greenland P., LaCroix A.Z., Stefanick M.L., Mouton C.P., Oberman A., Perri M.G., Sheps D.S., Pettinger M.B., Siscovick D.S. - Walking compared with vigorous exercise for the prevention of cardiovascular events in women. N. Engl. J. Med. 2002; 347:716-725.
44. Siscovick D.S., Weiss N.J., Fletcher R.H., Lasky T. - The incidence of primary cardiac arrest during vigorous exercise. N. Engl. J. Med. 1984; 311:984-987.
45. Goto C, Higashi Y., Kimura M., Noma K., Hara K., Nakagawa K., Kawamura M., Chayama K., Yoshizumi M., Nara I. - Effect of different intensities of exercise on endothelium-dependent vasodilation in humans: role of endothelium-dependent nitric oxide and oxidative stress. Circulation. 2003; 108:530-535.
46. Hambrecht R., Wolf A., Gielen S., Linke A., Hofer J., Erbs S., Schoene N., Schuler G. - Effect of exercise on coronary endothelial function in patients with coronary artery disease. N. Engl. J. Med. 2000; 342:454-460.
47. Rauramaa R., Halonen P., Vaisanen S.B., Lakka T.A., Schmidt-Trucksass A., Berg A., Penttila I.M., Rankinen T., Bouchard C - Effects of aerobic physical exercise on inflammation and atherosclerosis in men: the DNASCO study: a six-year randomized controlled trial. Ann. Intern. Med. 2004:140:1007-1014.
48. Stewart K.J. - Exercise training and the cardiovascular consequences of type 2 diabetes and hypertension: plausible mechanisms for improving cardiovascular health. J. Am. Med. Assoc. 2002; 288:1622-1631.
49. Lee K.W., Lip G.Y.H. - Effect of lifestyle on hemostasis, fibrinolysis, and platelet reactivity: a systematic review. Arch. Int. Med. 2003; 163:2368-2392.
50. Thompson P.D., Buchner D., Pina I.L., Balady G.J., Williams M.A., Marcus B.H., Berra K., Blair S.N., Costa F., Franklin B., Fletcher G.F., Gordon N.F., Pate R.R., Rodriguez B.L., Yancey A.K., Wenger N.K. - Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity). Circulation 2003; 107:3109-3116.
51. Pearson T.A. - New tools for coronary risk assessment: what are their advantages and limitations? Circulation. 2002; 105:886-892.
52. Maas R., Boger R.H. - Old and new cardiovascular risk factors: from unresolved issues to new opportunities. Atheroscler. Suppl. 2003; 4:5-17.
53. Colditz G.A., Rinim E.B., Giovannucci E., Stampfer M.J., Rosner B., Willett W.C. - A prospective study of parental history of myocardial infarction and coronary artery disease in men. Am. J. Cardiol. 1991; 67:933-938.
54. Cremer P., Nagel D., Mann H., Labrot B., Muller-Berninger R., Elster H., Seidel D. - Ten-year follow-up results from the Goettingen Risk, Incidence and Prevalence Study (GRIPS). I. Risk factors for myocardial infarction in a cohort of 5790 men. Atherosclerosis. 1997; 129:221-230.
55. Terry D.F., Pencina M.J., Vasan R.S., Murabito J.M., Wolf P.A., Hayes M.K., Levy D., D'Agostino R.B., Benjamin E.J. - Cardiovascular risk factors predictive for survival and morbidity-free survival in the oldest-old Framingham Heart Study participants. J. Am. Geriatr. Soc. 2005; 53:1944-1950.
56. Knopp R.H. - Risk factors for coronary artery disease in women. Am. J. Cardiol. 2002; 89:28E-34E.
57. Manson J.E., Hsia J., Johnson K.C., Rossouw J.E., Assaf A.R., Lasser N.L., Trevisan M., Black H.R., Heckbert S.R., Detrano R., Strickland O.L., Wong N.D., Crouse J.R., Stein E., Cushman M; Women's Health Initiative Investigators - Estrogen plus progestin and the risk of coronary heart disease. N. Engl. J. Med. 2003; 349:523-534.
58. Grodstein F., Manson J.E., Stampfer M.J. - Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J. Womens Health (Larchmt). 2006; 15:35-44.
59. Mendelsohn M.E., Karas R.H. - Molecular and cellular basis of cardiovascular gender differences. Science. 2005; 308:1583-1587.
60. Kannel W.B., Levy D. - Menopause, hormones, and cardiovascular vulnerability in women. Arch. Intern. Med. 2004; 164:479481.
61. Lloyd-Jones D.M., Nam B.H., D'Agostino R.B. Sr, Levy D., Murabito J.M., Wang T.J., Wilson P.W., O'Donnell C.J. - Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults: a prospective study of parents and offspring. JAMA. 2004; 291:2204-2211.
62. Tuomilehto J. - Impact of age on cardiovascular risk: implications for cardiovascular disease management. Atheroscler 2004; 5:9-17.
63. McCormick J. - The multifactorial aetiology of coronary heart disease: a dangerous delusion. Perspect Biol Med. 1988; 32:103-108.
64. Ahrens E.H. Jr - The management of hyperlipidemia: whether, rather than how. Ann. Intern. Med. 1976; 85:87-93.
65. Greenland P., Knoll M.D., Stamler J., Neaton J.D., Dyer A.R., Garside D.B., Wilson P.W. - Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA. 2003; 290:891-897.
66. Hunink M.G., Goldman L., Tosteson A.N., Mitdeman M.A., Goldman P.A., Williams L.W., Tsevat J., Weinstein M.C - The recent decline in mortality from coronary heart disease, 1980-1990. The effect of secular trends in risk factors and treatment. JAMA 1997, 277:535-542.
67. Unal B., Critchley J.A., Capewell S. - Modelling the decline in coronary heart disease deaths in England and Wales, 1981-2000: comparing contributions from primary prevention and secondary prevention. Br. Med. J. 2005; 331:614.
68. Fox C.S., Evans J.C., Larson M.G., Kannel W.B., Levy D. - Temporal trends in coronary heart disease mortality and sudden cardiac death from 1950 to 1999. The Framingham Heart Study. Circulation 2004; 110:522-527.
69. Pearson T.A., Blair S.N., Daniels S.R., Eckel R.H., Fair J.M., Fortmann S.P., Franklin B.A., Goldstein L.B., Greenland P., Grundy S.M., Hong Y., Miller N.H., Lauer R.M., Ockene I.S., Sacco R.L., Sallis J.F. Jr, Smith S.C. Jr, Stone N.J., Taubert K.A. - AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation. 2002; 106:388-391.
70. Collins R., Armitage J., Parish S., Sleigh P., Peto R; Heart Protection Study Collaborative Group - MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003; 361:2005-2016.
71. Hopkins P.N., Williams R.R. - A survey of 246 suggested coronary risk factors. Atherosclerosis. 1981; 40:1-52.
72. Manolio T. - Novel risk markers and clinical practice. N. Engl. J. Med. 2003; 349:1587-1589.
73. Edelman E.R. - On causes: Hippocrates, Aristotle, Robert Koch, and the Dread Pirate Roberts. Circulation. 2001; 104:2509-2512.
74. Pearson T.A., Mensah G.A., Alexander R.W., Anderson J.L., Cannon R.O. III, Criqui M., Fadl Y.Y., Fortmann S.P., Hong Y., Myers G.L., Rifai N., Smith S.C. Jr., Taubert K., Tracy R.P., Vinicor F.; Centers for Disease Control and Prevention; American Heart Association - Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003; 107:499-511.
75. Folsom A.R., Wu K.K., Rosamond W.D., Sharrett A.R., Chambless L.E. - Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 1997; 96:1102-1108.
76. Yarnell J.W.G., Patterson C.C., Sweeman P.M., Lowe G.D.O. - Haemostatic/inflammatory markers predict 10-year risk of IHD at least as well as lipids: the Caerphilly collaborative studies. Eur. Heart. J. 2004; 25:1049-1056.
77. Ernst E., Matrai A., Paulsen F. - Leukocyte rheology in recent stroke. Stroke 1987; 18:59-62.
78. Friedman G.D., Klatsky A.L., Siegelaub A.B. - The leukocyte count as a predictor of myocardial infarction. N. Engl. J. Med. 1974; 290:1275-1278.
79. Asano M., Branemark P.-I., Castenholz A. - A comparative study of continuous qualitative and quantitative analysis of microcirculation in man: microchymography and microphotoelectric plethysmography applied to microvascular investigation. Adv. Microcirc. 1973; 5:1-31.
80. Granger D.N. - Ischaemia-reperfusion: mechanism of microvascular dysfunction and the influence of risk factors for cardiovascular disease. Microcirculation 1999; 6:167-178.
81. Yarnell J.W.G., Sweetnam P.M., Elwood P.C., Eastham R., Gilmour R.A., O'Brien J.R., Etherington M.D. - Haemostatic factors and ischaemic heart disease. The Caerphilly Study. Br. Heart. J. 1985; 53:483-487.
82. Manttari M., Manninen V., Koskinen P., Huttunen J.K., Oksanen E., Tenkanen L., Heinonen P.P., Frick M.H. - Leukocytes as a coronary risk factor in a dyslipidemic male population. Am. Heart. J. 1992; 123:873-877.
83. Ensrud K., Grimm R.H. - The white blood cell count and risk for coronary heart disease. Am. Heart. J. 1992; 124:207-213.
84. Grimm R.H., Neaton J.D., Ludwing W. - Prognostic importance of the white blood cell count for coronary, cancer, and all-cause mortality. JAMA 1985; 254:1932-1937.
85. Chan-Yeung M., Buncio A.D. - Leukocyte count, smoking, and lung function. Am. J. Med. 1984; 76:31-37.
86. Zalokar J.B., Richard J.L., Claude J.R. - Leukocyte count, smoking, and myocardial infarction. N. Engl. J. Med. 1981; 304:465468.
87. Corre F., Lellouch J., Schwartz D. - Smoking and leukocyte counts: results of an epidemiologic survey. Lancet 1971; 2:632-634.
88. Lowe G.D., Machado S.G., Krol W.F., Barton B.A., Forbes C.D. - White blood cell count and haematocrit as predictors of coronary recurrence after myocardial infarction. Thromb. Haemost. 1985; 54:700-703.
89. Wilson P.W., Garrison R.J., Abbott R.D., Castelli W. - Factors associated with lipoprotein cholesterol levels. The Framingham study. Arteriosclerosis. 1983; 3: 273-281.
90. Mercuri M., Ciuffetti G., Robinson M., Toole J. - Blood cell rheology in acute cerebral infarction. Stroke 1989; 20:959-962.
91. Hansen L.K., Grimm R.H. Jr, Neaton J.D. - The relationship of white blood cell count to other cardiovascular risk factors. Int. J. Epidemiol. 1990; 19:881-888.
92. Galante A., Pietroiusti A., Domenici B., Magrini A., Carta S., Colace F., Dell'Uomo L., Cipriani C., Argiro G., Zulli L., Martinelli G. - Timing and course of leukocyte aggregation in myocardial infarction. Thromb. Haemost. 2005; 74:1221-1224.
93. Spodick D.H. - Inflammation and the onset of myocardial infarction. Ann. Intern. Med. 1985; 102:699-702.
94. Hammerschmidt D.E., Harris P.D., Wayland J.H., Craddock P.R., Jacob H.S. - Complement-induced granulocyte aggregation in vivo. Am. J. Pathol. 1981; 102:146-150.
95. Bagge U., Blixt A., Braide M. - Macromodel experiments on the effect of wall-adhering white cells on flow resistance. Clin. Hemorrheol. 1986; 6:365-372.
96. Alderman M.J., Bidge A., Morley A.A., Ryall R.G., Walsh J.A. - Effect of total leucocyte count on whole blood filterability in patients with peripheral vascular disease. J. Clin. Pathol. 1981; 34:163-166.
97. Lehr H.A., Menger M.D., Messmer K. - Impact of leukocyte adhesion on myocardial ischemia/reperfusion injury: conceivable mechanisms and proven facts. J. Lab. Clin. Med. 1993; 121:539-545.
98. Weissmann G., Smolen J.E., Korchak H.M. - Release of inflammatory mediators from stimulated neutrophils. N. Engl. J. Med. 1980; 303:27-34.
99. Mehta J.L., Nichols W.W., Mehta P. - Neutrophils as potential participants in acute myocardial ischemia: relevance to reperfusion. J. Am. Coll. Cardiol. 1988; 11:1309-1316.
100. Mehta J., Dinerman J., Mehta P., Saldeen T.G., Lawson D., Donnelly W.H., Wallin R. - Neutrophil function in ischemic heart disease. Circulation 1989; 79:549-556.
101. Harlan J.M., Killen P.D., Harker L.A., Striker G.E., Wright D.G. - Neutrophil-mediated endothelial injury in vitro mechanisms of cell detachment. J. Clin. Invest. 1981; 68:1394-1403.
102. Lucchesi B.R. - Role of neutrophils in ischemic heart disease: pathophysiologic role in myocardial ischemia and coronary artery reperfusion. Cardiovasc. Clin. 1987; 18:3548.
103. Chen J., Mehta J.L. - Role of oxidative stress in coronary heart disease. Indian Heart J. 2004; 56:163-173.
104. Simpson P.J., Todd R.F., Fantone J.C., Mickelson J.K., Griffin J.D., Lucchesi B.R. - Reduction of experimental canine myocardial reperfusion injury by a monoclonal antibody (anti-Mor, anti CD 11B) that inhibits leukocyte adhesion. J. Clin. Invest. 1988; 81:634-639.
105. Martini J., Cabrales P., Tsai A.G., Intaglietta M. - Mechanotransduction and the homeostatic significance of maintaining blood viscosity in hypotension, hypertension and haemorrhage. J. Intern. Med. 2006; 259:364-372.
106. Baskurt O.K., Meiselman H.J. - Blood rheology and hemodynamics. Semin. Thromb. Hemost. 2003; 29:435450.
107. Kannel W.B., Anderson K., Wilson P.W.F. - White blood cell count and cardiovascular disease. JAMA. 1992; 261:1253-1256.
108. Smith E.B. - Fibrinogen, fibrin and the arterial wall. Eur. Heart J. 1995; 16(Supl. A):11-14.
109. Danesh J., Collins R., Peto R., Lowe G.D.O. - Haematocrit, viscosity, erythrocyte sedimentation rate: meta-analyses of prospective studies of coronary heart disease. Europ. Heart J. 2000; 21:515-520.
110. Rampling M.W. - Haemorheology and the inflammatory process. Clin Hemorheol Microcirc. 1998; 19:129-132.
111. Schechner V., Shapira I., Berliner S., Comaneshter D., Hershcovici T., Orlin J., Zeltser D., Rozenblat M., Lachnri K., Hirsch M., Beigel Y. - Significant dominance of fibrinogen over immunoglobulins, C-reactive protein, cholesterol and triglycerides in maintaining increased red blood cell adhesiveness/aggregation in the peripheral venous blood: a model in hypercholesterolaemic patients. Eur. J. Clin. Invest. 2003; 33:955-961.
112. Fusman G., March T., Justo D., Rozenblat M., Rotstein R., Zeltser D., Rubinstein A., Koffler M., Shabtai E., Berliner S., Shapira I. - Red blood cell adhesiveness/aggregation, C-reactive protein, fibrinogen, and erythrocyte sedimentation rate in healthy adults and in those with atherosclerotic risk factors. Am. J. Cardiol. 2002; 90:561-563.
113. Krieger E., van Der Loo B., Amann-Vesti B.R., Rousson V., Koppensteiner R. - C-reactive protein and red cell aggregation correlate with late venous function after acute deep venous thrombosis. J. Vasc. Surg. 2004; 40:644-649.
114. Schuff-Werner P. - Increased red blood cell adhesiveness/aggregation owing to fibrinogen elevation in hypercholesterolaemic patients and the rationale of fibrinogen-lowering by LDL apheresis. Eur. J. Clin. Invest. 2004; 34:378-379.
115. Soutani M., Suzuki Y., Tateishi N., Maeda N. - Quantitative evaluation of flow dynamics of erythrocytes in microvessels: influence of erythrocyte aggregation. Am. J. Physiol. 1995; 268:H1959-H1965.
116. Bishop J.J., Nance P.R., Popel A.S., Intaglietta M., Johnson P.C. - Erythrocyte marginatum and sedimentation in skeletal muscle venules. Am. J. Physiol. Heart. Circ. Physiol. 2001; 281:H951-H958.
117. Yalcin O., Uyuklu M., Armstrong J.K., Meiselman H.J., Baskurt O.K. - Graded alterations of RBC aggregation influence in vivo blood flow resistance. Am. J. Physiol. Heart Circ. Physiol. 2004; 287:H2644-H2650.
118. Tateishi N., Suzuki Y., Shirai M., Cicha I., Maeda N. - Reduced oxygen release from erythrocytes by the acceleration-induced flow shift, observed in an oxygen-permeable narrow tube. J. Biomech. 2002; 35:1241-1251.
119. Baskurt O.K., Yalcin O., Ozdem S., Armstrong J.K., Meiselman H.J. - Modulation of endothelial nitric oxide synthase expression by red blood cell aggregation. Am. J. Physiol. Heart Circ. Physiol. 2004; 286:H222-H229.
120. Kwaan H.C., Sakurai S., Wang J. - Rheological abnormalities and thromboembolic complications in heart disease: spontaneous echo contrast and red cell aggregation. Semin. Thromb. Hemost. 2003; 29:529-534.
121. Rastegar R., Harnick D.J., Weidemann P., Fuster V., Coller B., Badhnon J.J., Chesebro J., Goldman M.E. - Spontaneous echo contrast videodensity is flow-related and is dependent on the relative concentrations of fibrinogen and red blood cells. J. Am. Coll. Cardiol. 2003; 41:603-610.
122. Berliner S., Rogowski O., Aharonov S., Mardi T., Tolshinsky T., Rozenblat M., Justo D., Deutsch V., Serov J., Shapira I., Zeltzer D. - Erythrocyte adhesiveness/aggregation: a novel biomarker for the detection of low-grade internal inflammation in individuals with atherothrombotic risk factors and proven vascular disease. Am. Heart J. 2005; 149:260-267.
123. Sargento L., Saldanha C., Monteiro J., Perdigão C., Martins e Silva J. - Long-term prognostic value of protein C activity, erythrocyte aggregation and membrane fluidity in transmural myocardial infarction. Thromb. Haemost. 2005; 94:380-388.
124. Meade T.W., Mellows S., Brozovic M., Miller G.J., Chakrabarti R.R., North W.R.S., Haines R.P., Stirling Y., Imeson J.D., Thompson S.G. - Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet. 1986; 2:533-637.
125. Wilhelmsen L., Svardsudd K., Korsan-Bengtsen K., Larsson B., Welin L, Tibblin G. - Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med. 1984; 34:501-505.
126. Yarnell J.W., Baker I.A., Sweetnam P.M., Bainton D., O'Brien J.R., Whitehead P.J., Elwood P.C. - Fibrinogen, viscosity and white blood cell count are major risk factors for ischemic heart disease. The Caerphilly and Speedwell Collaborative Heart Disease Studies. Circulation 1991; 83:836-844.
127. Ernst E., Resch K.L. - Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann. Intern. Med. 1993; 118:956-963.
128. Sargento L., Saldanha C., Monteiro J., Perdigão C., Martins e Silva J. - Evidence of prolonged disturbances in the haemostatic, hemorheologic and inflammatory profiles in transmural myocardial infarction survivors. Thromb. Haemost. 2003; 89:892-903.
129. Cooper J.A., Miller G.J., Rauer K.A., Morrisey J.H., Meade T.W., Howarth D.J., Barzegar S., Mitchell J.R., Rosenberg R,D. - Comparison of novel hemostatic factors and conventional risk factors for prediction of coronary heart disease. Circulation 2000; 102:2816-2822.
130. Scarabin P.Y., Arveiler D., Amouyel P., Dos Santos C., Evans A., Luc G., Ferrieres J., Juhan-Vague I - Prospective Epidemiological Study of Myocardial Infarction - Plasma fibrinogen explains much of the difference in risk of coronary heart disease between France and Northern Ireland. The PRIME study. Atherosclerosis. 2003; 166:103-109.
131. Lowe G.D.O. - Blood rheology and vascular disease. In: "Haemostasis and Thrombosis", A.L. Bloom, C.D. Forbes, D.P. Thomas, E.G.D. Tuddenham (eds). 3rd ed. Edinburgh: Churchill Livingstone 1994; 1169-1188.
132. Danesh J., Collins R., Appleby P., Peto R. - Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 1998; 279:1477-1482.
133. Whittington R.B., Harkness J. - Whole-blood viscosity, as determined by plasma viscosity, hematocrit, and shear. Biorheology 1982; 19:175-184.
134. Lowe G.D.O., MacArdle B.M., Stromberg P., Lorimer A.R., Forbes C.D., Prentice C.R. - Increased blood viscosity and fibrinolytic inhibitor in type II hyperlipoproteinaemia. Lancet 1982; 1:472475.
135. Koenig W., Sund M., Filipiak B., Doring A., Lowel H., Ernst E. - Plasma viscosity and the risk of coronary heart disease: results from the MONICA-Augsburg cohort study, 1984 to 1992. Arterioscler. Thromb. Vasc. Biol. 1998; 18:768-772.
136. Lowe G.D.O., Lee A.J., Rumley A., Price J.F., Fowkes F.G.R. - Blood viscosity and risk of cardiovascular events: the Edinburgh Artery Study. Br. J. Haematol. 1997; 96:168-173.
137. Lowe G., Rumley A., Norrie J., Ford I., Shepherd J., Cobbe S., Macfarlane P., Packard C., On behalf of the West of Scodand Coronary Prevention Study Groups. - Blood rheology, cardiovascular risk factors, and cardiovascular disease: the West of Scodand Coronary Prevention Study. Thromb. Haemost. 2000; 84:553-558.
138. Smith A, Patterson C., Yarnell J., Rumley A., Ben-Shlomo Y., Lowe G. - Which hemostatic markers add to the predictive value of conventional risk factors for coronary heart disease and ischemic stroke? The Caerphilly Study. Circulation. 2005; 112:3080-3087.
139. Davignon J., Ganz J. - Role of endothelial dysfunction in atherosclerosis. Circulation. 2004; 109:11127-11132.
140. Wierzbicki A.S., Chowienczyk P.J., Cockcroft J.T., Brett S.E., Watts G.F., Jenkins B.S., Ritter J.M. - Cardiovascular risk factors and endothelial dysfunction. Clin. Sci. 2004; 107:609-615.
141. Celermajer D.S., Sorensen K.E., Georgakopoulos D., Bull C. Thomas O., Robinson J., Deanfield J.E - Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation 1993; 88:2149-2155.
142. Chowienczyk P.J., Watts G.F., Cockcroft J.R., Ritter J.M. - Impaired endothelium-dependent vasodilation of forearm resistance vessels in hypercholesterolaemia. Lancet 1992; 340:1430-1432.
143. Clarkson P., Celermajer D.S., Powe A.J., Donald A.E., Henry R.M., Deanfield J.E. - Endothelium-dependent dilatation is impaired in young healthy subjects with a family history of premature coronary disease. Cirulation 1997; 96:3378-3383.
144. Ridker P.M., Brow N.J., Vaughan D.E., Harrison D.G., Mehta J.L. - Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. Circulation 2004; 109 (25 Suppl.):IV6-IV19.
145. Wassmann S., Wassmann K., Nickenig G. - Modulation of oxidant and antioxidant enzyme expression and function in vascular cells. Hypertension 2004; 44:381-386.
146. Cooke J.P., Dzau V.J. - Nitric oxide synthase: role in the genesis of vascular disease. Annu. Rev. Med. 1997; 48:489-508.
147. Richter B., Niessner A., Penka M., Grdic M., Steiner S., Strasser B., Ziegler S., Zorn G., Maurer G., Simeon-Rudolf V., Wojta J., Huber K. - Endurance training reduces circulating asymmetric dimethylarginine and myeloperoxidase levels in persons at risk of coronary events. Thromb. Haemost. 2005; 94:1306-1311.
148. Edwards D.G., Schofield R.S., Lennon S.L., Pierce E.L., Nichols W.W., Braith R.W. - Effect of exercise training on endothelial function in men with coronary artery disease. Am. J. Cardiol. 2004; 93:617-620.
149. Kannel W.B., Abbott R.D. - Incidence and prognosis of unrecognized myocardial infarction: an update from the Framingham study. N. Engl. J. Med. 1984; 311:1144-1147.
150. Anderson K.M., Odell P.M., Wilson P.W., Kannel W.B. - Cardiovascular disease risk profiles. Am. Heart J. 1991; 121:293-298.
151. Folsom A.R. - Hemostatic risk factors for atherothrombotic disease. Thromb. Haemost. 2001; 86:1-7.
152. Juhan-Vague I., Alessi M.C., Vague P. - Thrombogenic and fibrinolytic factors and cardiovascular risk in non-insulin-dependent diabetes mellitus. Ann. Med. 1996; 28:371-380.
153. Ross R. - Atherosclerosis: an inflammatory disease. N. Engl. J. Med. 1999; 340:115-126.
154. Ridker P.M. - Cardiology Patient Page. C-reactive protein: a simple test to help predict risk of heart attack and stroke. Circulation 2003; 108:e81-e85.
155. Lemieux I., Pascot A., Prud'homme D., Alméras N., Bogaty P., Nadeau A., Bergeron J., Després J.P. - Elevated C-reactive protein: another component of the atherothrombotic profile of abdominal obesity. Arterioscler. Thromb. Vasc. Biol. 2001; 21:961-967.
156. Fried S.K., Bunkin D.A., Greenber A.S. - Omental and subcutaneous adipose tissues of obese subjects release IL-6: depot difference and regulation by glucocorticoid. J. Clin. Endocrinol. Metab. 1998;83:847-850.
157. Castell J.V., Gomez-Lechon M.J., David M., Andus T, Geiger T., Trullenque R., Fabra R., Heinrich P.C. - II-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. FEBS Lett. 1989; 242:237-239.
158. Heilbronn L.K., Noakes M., Clifton P.M. - Energy restriction and weight loss on very-low-fat diets reduce C-reactive protein concentrations in obese, healthy women. Arterioscler. Thromb. Vasc. Biol. 2001; 21:968-970.
159. Church T.S., Barlow C.E., Earnest C.P., Kampert J.B., Priest E.L., Blair S.N. - Associations between cardiorespiratory fitness and C-reactive protein in men. Arterioscler. Thromb. Vasc. Biol. 2002; 22:1869-1876.
160. Grundy S.M., Brewer H.B.Jr. Cleeman J.I., Smith S.C.Jr., Lenfant C. - Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109:433438.
161. Third repost of the National Cholesteral Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Final report. Circulation 2002; 106:3143-3421.
162. Wannamethee G.S., Shaper A.G., Lennon L., Morris R.W. - Role of the metabolic syndrome in risk assessment for coronary heart disease. Arch. Intern. Med. 2005; 165:2644-2650.
163. Criqui M.H. - Peripheral arterial disease-epidemiological aspects. Vasc. Med. 2001; 6:3-7
164. Parikh N.I., Hwang S.J., Larson M.G., Meigs J.B., Levy D., Fox C.S. - Cardiovascular disease risk factors in chronic kidney disease: overall burden and rates of treatment and control. Arch. Intern. Med. 2006; 166:1884-1891.
165. Merlini P.A., Ardissino D. - Genetic polymorphisms to evaluate the risk of myocardial infarction: a long way away. Thromb. Haemost. 2001; 86:1136-1138.
166. Obisesan T.O., Leeuwenburgh C., Phillips T., Ferrell R.E., Phares D.A., Prior S.J., Hagberg J.M. -C-reactive protein genotypes affect baseline, but not exercise-training induced changes in C-reactive protein levels. Arterioscler. Thromb. Vasc. Biol. 2004; 24:1874-1879.
167. Collins F.S. - Shattuck Lecture - Medical and societal consequences of the human genome project. N. Engl. J. Med. 1999; 341:28-37
168. Lenfant C., Friedman L., Thorn T. - Fifty years of death certificates: the Framingham Heart Study. Ann. Int. Med. 1998; 129:1066-1067.